The United States anticonvulsant markets have seen dramatic growth over the past few years. Current product revenues are now seven times the revenues of a decade earlier. Second-generation products are offering doctors new weapons in the battle against epilepsy. Meanwhile, "off-label" applications such as the treatment of chronic pain or bipolar disorder are generating important new opportunities for market participants.

This Frost & Sullivan study examines the markets for both indicated and off-label uses for anticonvulsants. It evaluates markets for drugs that treat epilepsy, bipolar disorder, and other off-label uses, including chronic pain management and migraine prevention. By tracking emerging trends and identifying possible growth areas, this study provides its users with an important tool to realize the full potential of this field.

Second-Generation Products Provide Important Advances

"A number of second-generation anticonvulsants offer significant improvements in efficacy, tolerability, and ease of dosing for epileptics," says the analyst responsible for this study. Although medications to treat epilepsy have been available for decades, significant advances in medical products and technologies have occurred only within the past five years.

With approximately three million Americans suffering from epilepsy, drugs that prevent or minimize the effects of seizures will remain in great demand. This research reports key demographics for the U.S. epileptic population, tracks healthcare coverage issues, and surveys trends in product marketing. With its identification of new products in development and its assessment of their revenue potential, this study will give you an important advantage over competitors.

Off-Label Uses Present Both Prospects and Challenges

The potential profitability gains of off-label applications will continue to encourage companies to develop new uses for anticonvulsants. Eight times as many people suffer migraines than are afflicted with epilepsy. Chronic pain affects 50 million Americans. "Instead of viewing a market worth hundreds of million of dollars, participants are looking at multi-billion dollar opportunities," says the analyst.

Nevertheless, the lack of an FDA-approved indications for these alternative applications could serve as a barrier to market penetration. This study provides a solid understanding of the major off-label applications for anticonvulsants. By evaluating the impact of FDA approval and other challenges to off-label markets, this research will help your firm overcome hurdles and maximize returns.

1. Executive Summary
A. Executive Summary

2. Introduction and Methodology
A. Introduction
1. Introduction to the U.S. Anticonvulsant Market
2. Study Objectives
B. Methodology
1. Primary and Secondary Research
2. Frost and Sullivan's Market Forecasting Model

3. Total U.S. Anticonvulsant Market Overview
A. Introduction
1. Overview of Anticonvulsants on the U.S. Market
2. FDA-Approved First-Generation Anticonvulsants
3. FDA-Approved Second-Generation Anticonvulsants: 1993 - 1996
4. FDA-Approved Second-Generation Anticonvulsants: 1997 - 2000
5. Alternative Therapies
B. U.S. Anticonvulsant Market Performance: 1990 to 2000
1. U.S. Anticonvulsant Market Revenues: 1990 to 2000
2. Second-Generation Anticonvulsant Market Performance: 1997 to 2000
3. Market Engineering Analysis
C. Market Engineering Awards
1. Technology Innovation Award
2. Marketing Strategy Leadership Award
3. Product Differentiation Innovation Award
4. Product Launch Strategy Award

4. The Epilepsy Market
A. Disease Overview
1. Introduction
2. Epidemiology and Etiology
3. Clinical Presentation
B. Diagnosing and Treating Epilepsy
1. Diagnosing Epilepsy
2. Seizure Classification
3. Tolerability
4. Age and Medical Condition
5. Health Care Coverage
6. Epilepsy Market Potential For Second-Generation Anticonvulsants
C. Epilepsy Market Share Analysis (2000)
1. First-Generation Anticonvulsants
2. Second-Generation Anticonvulsants
D. Major Opportunities and Challenges
1. Challenges
2. Market Drivers
3. Market Restraints
E. Forecasts and Trends
1. Demand Analysis
2. Pricing Trends
3. Market and Technology Trends
4. First-Generation Anticonvulsant Revenues: Assumptions and Forecasts
5. Second-Generation Anticonvulsant Revenues: Assumptions and Forecasts
F. Strategic Recommendations
1. Strategies Overview
2. Strategic Recommendations for Market Challenge 1
3. Strategic Recommendations for Market Challenge 2
4. Strategic Recommendations for Market Challenge 3
5. Strategic Recommendations for Market Challenge 4

5. The U.S. Bipolar Disorder Market
A. Disease Overview
1. Introduction
2. Epidemiology and Etiology
3. Clinical Presentation
B. Diagnosing and Treating Bipolar Disorder
1. Diagnosing Bipolar Disorder
2. Goals of Treatment
3. Treatment Options
4. Bipolar Market Potential for Second-Generation Anticonvulsants
C. Bipolar Market Share Analysis (2000)
1. Front-Line Therapies: Mood Stabilizers
2. Second-Line Therapies: Second-Generation Anticonvulsants Vs. Atypical Antipsychotics
D. Major Opportunities and Challenges
1. Challenges
2. Market Drivers
3. Market Restraints
E. Forecast and Trends (2001 to 2005)
1. Market and Technology Trends
2. Revenue Forecasts
F. Strategic Recommendations
1. Strategies Overview
2. Strategic Recommendations for Market Challenge 1
3. Strategic Recommendations for Market Challenge 2

6. Other Off-Label Markets
A. Overview
1. Introduction
B. Pain Markets
1. Overview of the U.S. Pain Market
2. Pain Treatment Options
3. The Pain Market Potential for Anticonvulsants
C. Migraine Prophalaxis Markets
1. Overview of the U.S. Migraine Prophylaxis Market
2. Migraine Prophylaxis Treatment Options
3. The Migraine Prophylaxis Market Potential for Anticonvulsants

List of Figures

Chapter 3
Total Anticonvulsant Market: FDA-Approved First-Generation Products (U.S.), 2000
Total Anticonvulsant Market: FDA-Approved Second-Generation Products (U.S.), 1993-1996
Total Anticonvulsant Market: FDA-Approved Second-Generation Products (U.S.), 1997-2000
Total Patient Population: CNS Disorders (U.S.), 2000

Chapter 4
Epilepsy Market: Age-Wise Patient Profile (U.S.), 2000
Total Epilepsy Population: Classification of Epileptic Seizures (U.S.), 2000
First-Generation Anticonvulsant Epilepsy Market: Market Shares (U.S.), 2000
Second-Generation Anticonvulsant Epilepsy Market: Market Shares (U.S.), 2000
Anticonvulsant Epilepsy Market: Impact of Top Industry Challenges (U.S.), 2000-2005
Anticonvulsant Epilepsy Market: Market Drivers Ranked in Order of Impact (U.S.), 2000-2005
Anticonvulsant Epilepsy Market: Market Restraints Ranked in Order of Impact (U.S.), 2000-2005
Anticonvulsant Market: Annual Cost of Therapy (U.S.), 2000
First-Generation Anticonvulsant Epilepsy Market: Revenue Forecasts (U.S.), 1997-2005
Second-Generation Anticonvulsant Epilepsy Market: Revenue Forecasts (U.S.), 1997-2005
Anticonvulsant Epilepsy Market: Challenges and Strategic Recommendations (U.S.), 2000-2005

Chapter 5
Frontline Anticonvulsant Bipolar Market Revenues: Market Shares (U.S.), 2000
Second-Generation Anticonvulsant Bipolar Market Revenues: Market Shares (U.S.), 2000
Anticonvulsant Bipolar Market: Impact of Top Industry Challenges (U.S.), 2000-2005
Anticonvulsant Bipolar Market: Market Drivers Ranked in Order of Impact (U.S.), 2000-2005
Anticonvulsant Bipolar Market: Market Restraints Ranked in Order of Impact (U.S.), 2000-2005
Anticonvulsant Bipolar Market: Revenue Forecasts (U.S.), 1997-2005
Anticonvulsant Bipolar Market: Challenges and Strategic Recommendations (U.S.), 2000-2005